We also recently showed that CHFR promoter CpG island methylation is an indicator of poor survival in stage II BRAF wild type microsatellite stable CRC (n = 66, P < 0.01, HR = 3.89, 95 % CI = 1.58–9.60) and validated these results in an independent prospective cohort study (n = 136, P = 0.07, HR = 2.11, 95 % CI = 0.95–4.59) (Cleven et al., submitted). The gene discussed is CHFR; the disease is colorectal carcinoma.